It's hard to find a more disappointing stock in the medical device world this year than Edwards Lifesciences (NYSE: EW ) . This innovative company has rallied behind its Sapien transcatheter heart valve, but Edwards's stock hasn't impressed anyone in 2013: Shares have fallen more than 18% this year to date, even as the stock has recovered some of its losses in 2014.
Competition's breathing down Edwards' throat, even as the company protects its first-mover advantage in the U.S. Edwards won a big injunction in Germany against rival Medtronic (NYSE: MDT ) and its competing CoreValve, but Medtronic's still pushing ahead in this growing market. Meanwhile, Boston Scientific (NYSE: BSX ) and St. Jude Medical (NYSE: STJ ) are moving in on the Sapien with rival products of their own.
Can Edwards hold off the competition in order to establish the Sapien's dominance in the U.S., Japan, and other top markets? In the video below, Motley Fool contributor Dan Carroll tells you what you need to know about this innovative company's flagship product-and whether or not the Sapien can help Edwards's stock bounce back for investors.
Beefing up your portfolio's growth
One of the best ways to unlock your best growth opportunities in health care is to find companies like Edwards that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.